Abken H - Search Results

1

De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K, Kerre T, Abken H, Vandekerckhove B. De Munter S, et al. Among authors: abken h. Int J Mol Sci. 2018 Jan 30;19(2):403. doi: 10.3390/ijms19020403. Int J Mol Sci. 2018. PMID: 29385713 Free PMC article.

2

CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.

Kofler DM, Chmielewski M, Rappl G, Hombach A, Riet T, Schmidt A, Hombach AA, Wendtner CM, Abken H. Kofler DM, et al. Among authors: abken h. Mol Ther. 2011 Apr;19(4):760-7. doi: 10.1038/mt.2011.9. Epub 2011 Feb 15. Mol Ther. 2011. PMID: 21326215 Free PMC article.

3

IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.

Chmielewski M, Kopecky C, Hombach AA, Abken H. Chmielewski M, et al. Among authors: abken h. Cancer Res. 2011 Sep 1;71(17):5697-706. doi: 10.1158/0008-5472.CAN-11-0103. Epub 2011 Jul 8. Cancer Res. 2011. PMID: 21742772

4

An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack.

Jahn T, Zuther M, Friedrichs B, Heuser C, Guhlke S, Abken H, Hombach AA. Jahn T, et al. Among authors: abken h. PLoS One. 2012;7(9):e44482. doi: 10.1371/journal.pone.0044482. Epub 2012 Sep 18. PLoS One. 2012. PMID: 23028547 Free PMC article.

5

The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells.

Hombach AA, Holzinger A, Abken H. Hombach AA, et al. Among authors: abken h. Curr Mol Med. 2013 Aug;13(7):1079-88. doi: 10.2174/1566524011313070003. Curr Mol Med. 2013. PMID: 23116267 Review.

6

Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy.

Riet T, Holzinger A, Dörrie J, Schaft N, Schuler G, Abken H. Riet T, et al. Among authors: abken h. Methods Mol Biol. 2013;969:187-201. doi: 10.1007/978-1-62703-260-5_12. Methods Mol Biol. 2013. PMID: 23296935 Review.

7

Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

Hombach AA, Rappl G, Abken H. Hombach AA, et al. Among authors: abken h. Mol Ther. 2013 Dec;21(12):2268-77. doi: 10.1038/mt.2013.192. Epub 2013 Aug 28. Mol Ther. 2013. PMID: 23985696 Free PMC article.

8

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.

Chmielewski M, Hombach AA, Abken H. Chmielewski M, et al. Among authors: abken h. Immunol Rev. 2014 Jan;257(1):83-90. doi: 10.1111/imr.12125. Immunol Rev. 2014. PMID: 24329791 Review.

9

Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma.

Riet T, Abken H. Riet T, et al. Among authors: abken h. Expert Rev Hematol. 2015 Aug;8(4):383-5. doi: 10.1586/17474086.2015.1043884. Epub 2015 May 6. Expert Rev Hematol. 2015. PMID: 25946901

10

TRUCKs: the fourth generation of CARs.

Chmielewski M, Abken H. Chmielewski M, et al. Among authors: abken h. Expert Opin Biol Ther. 2015;15(8):1145-54. doi: 10.1517/14712598.2015.1046430. Epub 2015 May 18. Expert Opin Biol Ther. 2015. PMID: 25985798 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

225 results

Search Page